Avidity Biosciences Stock Price, News & Analysis
Company Description
Avidity Biosciences (RNAM) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $11.2B.
On a trailing twelve-month basis, Avidity Biosciences reported revenue of $18.8M with net income of -$684.6M and diluted earnings per share of $-4.97. The company operates at a net profit margin of -3650.4%.
This page provides a comprehensive overview of RNAM stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Latest News
SEC Filings
Avidity Biosciences has filed 1 recent SEC filing, including 1 Form 15-12G. The most recent filing was submitted on March 9, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all RNAM SEC filings →
Financial Highlights
Avidity Biosciences generated $18.8M in revenue over the trailing twelve months, operating income reached -$745.9M (-3977.3% operating margin), and net income was -$684.6M, reflecting a -3650.4% net profit margin. Diluted earnings per share stood at $-4.97. The company generated -$650.4M in operating cash flow. With a current ratio of 9.20, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Days to Cover History
RNAM Company Profile & Sector Positioning
Avidity Biosciences (RNAM) operates in the Biotechnology industry within the broader Healthcare sector.